DUBLIN, Aug 13, 2018 /PRNewswire/ --
The "Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from USD 28.91 billion in 2018 at a CAGR of 24.2% during the forecast period.
The growth of this market is primarily driven by factors such as the growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and the availability of generic versions of autoinjectors.
The autoinjectors market is segmented on the basis of therapy, type, end user, and region. Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies (such as migraines, cardiovascular diseases, psoriasis, and anemia). The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the high prevalence of rheumatoid arthritis across the globe.
Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the benefits disposable autoinjectors offer, such as portability, ease of use, and low possibility of infection.
Based on end user, the global autoinjectors market is categorized into home care settings and hospital & clinics. The home care settings segment is expected to register the highest CAGR during the forecast period due to the growing demand for self-administration drug delivery devices and the growing prevalence of chronic diseases.
Geographic segments in this report include North America, Europe, Asia Pacific, and RoW. Of these, the North American region is expected to account for the largest share of the market in 2018. The large share of this region can be attributed to the rising prevalence of autoimmune and chronic diseases, rising prevalence of anaphylaxis, and favorable reimbursement scenario in this region.
Preference for alternative drug delivery modes such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market during the forecast period to a certain extent.
The global autoinjectors market is dominated by Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US).
These players adopted growth strategies such as product launches, product approvals, agreements and expansions to maintain and enhance their position in the market.
Other prominent players in the market include Ypsomed (Switzerland), Merck (Germany), AstraZeneca (UK), J&J (US), Bayer (Germany), Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Autoinjectors Market Overview
4.2 Autoinjectors Market, By Type, 2018 vs 2023
4.3 Geographic Analysis: Autoinjectors Market, By Therapy
4.4 Autoinjectors Market, By End User, 2018 vs 2023
4.5 Geographic Snapshot: Autoinjectors Market
5 Market Overview
5.2 Market Dynamics
220.127.116.11 Growing Prevalence of Targeted Therapies
18.104.22.168 Rising Incidence of Anaphylaxis
22.214.171.124 Increasing Number of Regulatory Approvals
126.96.36.199 Availability of Generic Versions of Autoinjectors
188.8.131.52 Favorable Reimbursements and Government Support
184.108.40.206 Technological Advancements and Design Development
220.127.116.11 Preference for Alternative Drug Delivery Modes
18.104.22.168.1 Oral Diabetic Agents and Oral Insulin
22.214.171.124.2 Epinephrine Nasal Sprays
126.96.36.199 Patent Expiry of Biologics to Drive the Demand for Biosimilars
188.8.131.52 Development of Autoinjectors for Multiple Drug Viscosities
184.108.40.206 Lack of Proper Training for Using Autoinjectors
6 Autoinjectors Market, By Therapy
6.2 Rheumatoid Arthritis
6.3 Multiple Sclerosis
6.6 Other Therapies
7 Autoinjectors Market, By Type
7.2 Disposable Autoinjectors
7.3 Reusable Autoinjectors
8 Autoinjectors Market, By End User
8.2 Home Care Settings
8.3 Hospitals & Clinics
9 Autoinjectors Market, By Region
10 Competitive Landscape
10.2 Market Share Analysis
10.3 Market Ranking of OEM Companies
10.4 Market Share Analysis, By Therapeutic Area
10.4.1 Rheumatoid Arthritis
10.4.2 Multiple Sclerosis
10.5 Competitive Scenario
10.5.1 Product Launches and Approvals
10.5.3 Agreements, Collaborations, and Partnerships
11 Company Profiles
11.3 ELI Lilly
11.6 Becton, Dickinson and Company
11.7 Owen Mumford
11.8 Consort Medical
11.10 Shl Group (Scandinavian Health Limited)
11.11 Johnson & Johnson (J&J)
11.13 Antares Pharma
For more information about this report visit https://www.researchandmarkets.com/research/63rlb7/global?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets